{"entity":{"id":"adagloxad-simolenin","kind":"drug","name":"Adagloxad simolenin","aka":[],"tldr":"Adagloxad simolenin is OBI Pharma's vaccine against the tumour sugar Globo H, in the phase 3 GLORIA trial as adjuvant treatment for triple-negative breast cancer that expresses the antigen.","summary":"OBI Pharma of Taiwan developed adagloxad simolenin (OBI-822) from Samuel Danishefsky's Globo H synthesis. After a phase 2 trial in metastatic breast cancer showed benefit only in patients who mounted an antibody response, the phase 3 GLORIA trial tests it with the adjuvant OBI-821 in the adjuvant setting for Globo H-positive triple-negative breast cancer at high risk of recurrence.","status":"phase-3","asOf":"2026-09-16","links":[{"label":"ClinicalTrials.gov: trials of Adagloxad simolenin","url":"https://clinicaltrials.gov/search?intr=OBI-822"}],"tags":["pipeline","ctgov-ingest"],"related":[],"cancers":["tnbc"],"sections":[],"technologies":["dendritic-cell-vaccines"],"targets":[],"drugs":[],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":["nct03562637"],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"notes":[],"provenance":{"editedBy":"OnCo ingestion (ClinicalTrials.gov v2, curated)","editedOn":"2026-09-16"},"code":"OBI-822","modality":"Carbohydrate antigen vaccine (Globo H conjugate) with the adjuvant OBI-821","mechanism":"A Globo H glycan conjugated to a carrier protein, given with a saponin adjuvant, to raise antibodies against Globo H, a sugar antigen on breast and other epithelial cancer cells.","approvals":[],"mechanismSteps":[],"toxicity":[],"access":[],"regulatoryEvents":[]},"route":"/drugs/adagloxad-simolenin/","neighbours":{"cancer":[{"id":"tnbc","kind":"cancer","name":"Triple-negative breast cancer (TNBC)","route":"/cancers/tnbc/"}],"technology":[{"id":"dendritic-cell-vaccines","kind":"technology","name":"Dendritic cell vaccines","route":"/technologies/dendritic-cell-vaccines/"}],"trial":[{"id":"nct03562637","kind":"trial","name":"Study of Adagloxad Simolenin (OBI-822)/OBI-821 in the Adjuvant Treatment of Patients With Globo H Positive TNBC","route":"/trials/nct03562637/"}]}}